Cryoport to Provide Global Logistics Support for ISCO Trial

Cryoport, Inc. will provide global logistics support to International Stem Cell Corp.’s (ISCO) for its Phase I trial in Australia for the treatment of moderate to severe Parkinson’s disease. ISCO recently began patient enrollment.
 
Two of Cryoport’s depots in southern California and Singapore, will provide logistics support for the study from ISCO’s research facility in California to the study site in Australia. Cryoport specializes in the movement of high-value biologic material for clinical trials and commercialization programs globally and provides fully documented chain of custody and chain of condition data.
 
“This trial will take place across the globe and it is imperative that our cell therapy maintains integrity. We are pleased to have Cryoport handle our global logistics requirements,” said Russell Kern, Ph.D., executive vice president and chief scientific officer of ISCO.
 
Jerrell Shelton, chief executive officer of Cryoport, said, “Cryoport is proud to work with ISCO and support its efforts. We are fully confident in our ability to manage the logistics of the therapies as specified – and with certainty. We look forward to furthering our relationship with ISCO as we move forward.”